Cargando…
Decisions by regulatory agencies: are they evidence-based?
Contradictory statements about the non-steroidal anti-inflammatory drugs from the European Medicines Agency and the United States Food and Drug Administration have raised questions about whether regulatory decisions are evidence-based. For the selective COX-2 inhibitors, there are clear contraindica...
Autor principal: | Furberg, Curt D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852571/ https://www.ncbi.nlm.nih.gov/pubmed/17428328 http://dx.doi.org/10.1186/1745-6215-8-13 |
Ejemplares similares
-
The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions
por: Furberg, Curt D
Publicado: (2001) -
Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label
por: Dal-Ré, Rafael, et al.
Publicado: (2021) -
Withdrawal of cerivastatin from the world market
por: Furberg, Curt D, et al.
Publicado: (2001) -
Revolving doors and conflicts of interest in health regulatory agencies in Brazil
por: Scheffer, Mário C, et al.
Publicado: (2020) -
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
por: Ncube, Bakani Mark, et al.
Publicado: (2021)